The Chilean Council for Innovation and Competitiveness (CNIC), a group of advisers to President Bachelet on science policy and funding, decided late last year that they needed a outside opinion on the state of Biotechnology in Chile. Apparently, the topic was a contentious one within the Council and, to dispel doubts and obtain guidance uncontaminated by local interests, they solicited the help of Interlink Biotechnologies, LLC, a consulting company out of Princeton, NJ. Their report is entitled “Biotechnology assessment and strategic recommendations” and was produced in December of last year after a six day visit by three of the companies’ experts. The full report is available on the CNIC web site.
The conclusions have created somewhat of a stir as they start by dividing Chilean biotech into three categories: those topics aligned with local industry, those somewhat aligned and those not aligned. Among the latter category (and thus the stir) are the biomedical programs, which according to the report: “In spite of a large resource allocation, there is a minimal probability of success due to extremely competitive and well-funded global activity and a fundamental lack of relationship with the industry served”. In other words, the government should not specifically support the development of a strong biomedical capacity and should rather concentrate on areas that are more directly related to industries where Chile can compete (food, mining and energy). While this sounds logical to those in charge of allocating funds, it so happens that a very significant fraction of Chilean biologists (including the most productive ones) are doing research in what could be classified as biomedicine. These scientists had been relying on the notion that their basic research could be “sold” to funding agencies as applied because there is always the possibility of discovering some new drug target, or potential intervention for such and such a disease, etc. If the report is taken seriously by granting agencies, many of these researchers will be left to compete over the rather smallish funds that support basic science.
Apparently, the byproducts of the high level research carried out by this community (training of young scientists, networks with the first world, and just plain good science) are given a lower value in terms of economic impact, even in the long run. With only about 2000 active scientists in the country, can we afford to go after “products” risking to drop some of the best assets we have along the way? Shouldn’t the build-up of a solid scientific base come first and then a push for high tech industry? Do I have to even ask this?